Metabolic engineering generates a transgene-free safety switch for cell therapy
10.1038/s41587-020-0580-6 · doi-reference
Linking a cell-division gene and a suicide gene to define and improve cell therapy safety
10.1038/s41586-018-0733-7 · doi-reference
Is hypoimmunogenic stem cell therapy safe in times of pandemics?
10.1016/j.stemcr.2022.02.014 · doi-reference
How safe are universal pluripotent stem cells?
10.1016/j.stem.2020.02.006 · doi-reference
Survival of Transplanted allogeneic beta cells with no immunosuppression
10.1056/nejmoa2503822 · doi-reference
1318-OR: CNTY-813: scalable production of allo-evasion 5.0-Engineered IPSC beta islets for off-the-shelf cell therapies
10.2337/db26-1318-or · doi-reference
POS0056 CNTY-101, AN iPSC-DERIVED ALLOGENEIC CD19 TARGETING CAR-NK PRODUCT, EXHIBITS ROBUST B CELL DEPLETION AND HAS BROAD POTENTIAL FOR DEVELOPMENT IN B CELL-DRIVEN AUTOIMMUNE DISEASES
10.1016/j.ard.2025.05.453 · doi-reference
Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease
10.1038/s41586-025-08700-0 · doi-reference
Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: first three case reports
10.3389/fcvm.2023.1182209 · doi-reference
Accurate quantification and characterization of Adeno-Associated viral vectors
10.3389/fmicb.2019.01570 · doi-reference
Clearance of residual genome editing components used for ex vivo genome-editing of allogeneic cell therapy products
10.1016/j.jcyt.2024.06.005 · doi-reference
PCR-based analytics of gene therapies using adeno-associated virus vectors: considerations for cGMP method development
10.1016/j.omtm.2023.101132 · doi-reference
Cas9 immunity creates challenges for CRISPR gene editing therapies
10.1038/s41467-018-05843-9 · doi-reference
Identification of preexisting adaptive immunity to Cas9 proteins in humans
10.1038/s41591-018-0326-x · doi-reference
Immune responses to viral gene therapy vectors
10.1016/j.ymthe.2020.01.001 · doi-reference
Mechanisms underlying structural variant formation in genomic disorders
10.1038/nrg.2015.25 · doi-reference
De novo CNV formation in mouse embryonic stem cells occurs in the absence of Xrcc4-dependent nonhomologous end joining
10.1371/journal.pgen.1002981 · doi-reference
CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations
10.1038/s41467-022-28244-5 · doi-reference
Whole genomic analysis reveals atypical non-homologous off-target large structural variants induced by CRISPR-Cas9-mediated genome editing
10.1038/s41467-023-40901-x · doi-reference
Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing
10.1126/sciadv.abo7676 · doi-reference
Mechanisms for structural variation in the human genome
10.1007/s40142-013-0012-8 · doi-reference
Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells
10.1007/s00439-023-02561-1 · doi-reference
Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage
10.1038/s41598-020-59026-y · doi-reference
Comparison of exome and genome sequencing technologies for the complete capture of protein-coding regions
10.1002/humu.22813 · doi-reference
Pan-cancer analysis of non-coding recurrent mutations and their possible involvement in cancer pathogenesis
10.1093/narcan/zcab008 · doi-reference
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
10.1038/s41586-020-1965-x · doi-reference
Whole genome and exome sequencing reference datasets from a multi-center and cross-platform benchmark study
10.1038/s41597-021-01077-5 · doi-reference
Comprehensive assessment of on- and off-target mutagenesis via lipid nanoparticle delivery of CRISPR-Cas9 genome editing
10.1016/j.omtn.2026.102958 · doi-reference
The sequence of the human genome
10.1126/science.1058040 · doi-reference
The status of the human gene catalogue
10.1038/s41586-023-06490-x · doi-reference
Distinctive clinical and pathologic features of immature teratomas arising from induced pluripotent stem cell-derived beta cell injection in a diabetes patient
10.1089/scd.2021.0255 · doi-reference
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
10.1038/s41568-018-0060-1 · doi-reference
Copy number variation: new insights in genome diversity
10.1101/gr.3677206 · doi-reference
Hotspots of Human mutation
10.1016/j.tig.2020.10.003 · doi-reference
Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application
10.1016/j.omtm.2022.05.010 · doi-reference
Genetically engineered hypoimmunogenic cell therapy
10.1038/s44222-024-00219-9 · doi-reference
Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants
10.1038/s41467-019-13113-5 · doi-reference
Skin graft rejection by beta 2-microglobulin-deficient mice
10.1084/jem.175.4.885 · doi-reference
P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities
10.1084/jem.178.2.597 · doi-reference
HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells
10.1073/pnas.90.24.12000 · doi-reference
